HomeInsightsStock Comparison

Alkem Laboratories Ltd vs Cipla Ltd Stock Comparison

Alkem Laboratories Ltd vs Cipla Ltd Stock Comparison

Last Updated on: Jun 10, 2025

Key Highlights

  • The Latest Trading Price of Alkem Laboratories Ltd is ₹ 4950 as of 10 Jun 10:32.
  • The P/E Ratio of Alkem Laboratories Ltd changed from 24.7 on March 2020 to 32.9 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 years.
  • The Market Cap of Alkem Laboratories Ltd changed from ₹ 27844 crore on March 2020 to ₹ 59067 crore on March 2024 . This represents a CAGR of 16.23% over 5 yearsThe Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 years.
  • The revenue of Alkem Laboratories Ltd for the Mar '25 is ₹ 3289 crore as compare to the Dec '24 revenue of ₹ 3467 crore. This represent the decline of -5.12% The revenue of Cipla Ltd for the Mar '25 is ₹ 7019 crore as compare to the Dec '24 revenue of ₹ 7294 crore. This represent the decline of -3.78%.
  • The ebitda of Alkem Laboratories Ltd for the Mar '25 is ₹ 537.25 crore as compare to the Dec '24 ebitda of ₹ 852.38 crore. This represent the decline of -36.97% The ebitda of Cipla Ltd for the Mar '25 is ₹ 1827 crore as compare to the Dec '24 ebitda of ₹ 2210 crore. This represent the decline of -17.35%.
  • The net profit of Alkem Laboratories Ltd changed from ₹ 287.81 crore to ₹ 323.01 crore over 8 quarters. This represents a CAGR of 5.94% The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1225 crore over 8 quarters. This represents a CAGR of 10.87% .
  • The Dividend Payout of Alkem Laboratories Ltd changed from 23.64 % on March 2020 to 27.37 % on March 2024 . This represents a CAGR of 2.97% over 5 yearsThe Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alkem Laboratories Ltd

  • Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations.
  • The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
  • The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets.
  • With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales.
  • The company also has presence in more than 40 international markets, with the United States being its key focus market. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988.

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

Alkem Laboratories Ltd News Hub

News

Volumes spurt at Alkem Laboratories Ltd counter

Tata Technologies Ltd, Aditya Birla Fashion & Retail Ltd, Kaynes Technology India Ltd, Sun...

Read more

04 Jun 2025 11:00

News

Alkem Laboratories to conduct AGM

Alkem Laboratories announced that the 51th Annual General Meeting(AGM) of the company will...

Read more

29 May 2025 17:45

News

Board of Alkem Laboratories recommends final dividend

Alkem Laboratories announced that the Board of Directors of the Company at its meeting hel...

Read more

29 May 2025 17:27

News

Alkem Laboratories to discuss results

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 29 May ...

Read more

17 May 2025 15:23

News

Alkem MedTech acquires Bombay Ortho Industries

Alkem Laboratories announced that its wholly owned subsidiary, Alkem MedTech has completed...

Read more

17 Apr 2025 09:43

News

Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho

In February this year, Alkem Medtech had executed a binding offer outlining the terms and ...

Read more

17 Apr 2025 14:49

Cipla Ltd News Hub

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

News

Cipla to convene AGM

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 1...

Read more

14 May 2025 15:08

News

Board of Cipla recommends final dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Board of Cipla recommends special dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%

On the segmental front, the company's India business revenue was Rs 2,622 crore (up 8% YoY...

Read more

13 May 2025 15:17

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Alkem Laboratories Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alkem Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alkem Laboratories Ltd and Cipla Ltd

Which company has a larger market capitalization, Alkem Laboratories Ltd or Cipla Ltd?

Market cap of Alkem Laboratories Ltd is 58,280 Cr while Market cap of Cipla Ltd is 121,666 Cr

What are the key factors driving the stock performance of Alkem Laboratories Ltd and Cipla Ltd?

The stock performance of Alkem Laboratories Ltd and Cipla Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alkem Laboratories Ltd and Cipla Ltd?

As of June 10, 2025, the Alkem Laboratories Ltd stock price is INR ₹4874.4. On the other hand, Cipla Ltd stock price is INR ₹1506.35.

How do dividend payouts of Alkem Laboratories Ltd and Cipla Ltd compare?

To compare the dividend payouts of Alkem Laboratories Ltd and Cipla Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions